<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04763109</url>
  </required_header>
  <id_info>
    <org_study_id>IIT2020-23-BACA-MRINF1</org_study_id>
    <nct_id>NCT04763109</nct_id>
  </id_info>
  <brief_title>Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence</brief_title>
  <official_title>Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nicole Baca</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm pilot trial of a novel whole-body Magnetic Resonance Imaging paired with&#xD;
      artificial intelligence intervention, to evaluate feasibility defined as scan-rescan&#xD;
      reliability, and to estimate the positive predictive value of changes in Magnetic Resonance&#xD;
      Imaging scans from baseline to 12-month visit using an Artificial Intelligence algorithm,&#xD;
      among 15 pediatric patients with neurofibromatosis type 1 at Cedars-Sinai Medical Center.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>For scan re-scan reliability, utilize T2 imaging to evaluate the agreement between the baseline scan and the 1 Month scan, which is performed within 4 weeks of the baseline scan.</measure>
    <time_frame>From Baseline to within 4 weeks of baseline</time_frame>
    <description>T2 is a type of high-resolution multiparametric tissue mapping that measures quantitative metrics of the physical properties of tissue and allows comparison in longitudinal follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>For change over time, the initial scan imaging using T1 and apparent diffusion coefficient (ACD) imaging, the baseline scan will be compared to the third scan, which is performed 12 months (+/- 3 months) after the baseline scan.</measure>
    <time_frame>From Baseline to 12 months</time_frame>
    <description>T1 and ACD is a type of high-resolution multiparametric tissue mapping that measures quantitative metrics of the physical properties of tissue and allows comparison in longitudinal follow-up</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Neurofibromatosis Type 1</condition>
  <arm_group>
    <arm_group_label>Whole-Body Magnetic Resonance Imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Whole-body Magnetic Resonance Imaging</intervention_name>
    <description>Whole-body Magnetic Resonance Imaging at baseline, 1 month, and 12 months</description>
    <arm_group_label>Whole-Body Magnetic Resonance Imaging</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between the ages of 5 and &lt;18 years at the start of study. If subject will turn 18&#xD;
             during the study, they will be allowed to enroll.&#xD;
&#xD;
          -  Clinically or molecularly confirmed diagnosis of NF-1. Subjects with mosaic/segmental&#xD;
             NF-1 also qualify for the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Requiring sedation for imaging.&#xD;
&#xD;
          -  Implants and/or Devices: Mechanical, magnetic or electrical activated implants;&#xD;
             Ferromagnetic implants and foreign bodies&#xD;
&#xD;
          -  Claustrophobia, problems being in enclosed spaces, or inability to lie facing upwards.&#xD;
&#xD;
          -  Allergy to animal dander or animal-instigated asthma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicole Baca, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy Oppenheim</last_name>
    <phone>310-423-3713</phone>
    <email>Amy.Oppenheim@cshs.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Amy Oppenheim</last_name>
      <phone>310-423-3713</phone>
      <email>Amy.Oppenheim@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Fataneh Majlessipour, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pedro Sanchez, MD, MSCE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edwin Posadas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Debiao Li, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yibin Xie, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Touseef Qureshi, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 17, 2021</study_first_submitted>
  <study_first_submitted_qc>February 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Nicole Baca</investigator_full_name>
    <investigator_title>Assistant Professor of Department of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <keyword>Neurofibromatosis Type 1</keyword>
  <keyword>magnetic resonance imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurofibromatoses</mesh_term>
    <mesh_term>Neurofibromatosis 1</mesh_term>
    <mesh_term>Neurofibroma</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

